XTX Topco Ltd Grows Position in 2seventy bio, Inc. (NASDAQ:TSVT)

XTX Topco Ltd raised its position in shares of 2seventy bio, Inc. (NASDAQ:TSVT) by 61.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,416 shares of the company’s stock after acquiring an additional 9,257 shares during the period. XTX Topco Ltd’s holdings in 2seventy bio were worth $115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of TSVT. Nisa Investment Advisors LLC bought a new stake in 2seventy bio in the second quarter worth $52,000. Bank of New York Mellon Corp raised its position in shares of 2seventy bio by 5.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 196,959 shares of the company’s stock valued at $758,000 after buying an additional 10,077 shares in the last quarter. BBR Partners LLC raised its position in shares of 2seventy bio by 66.7% during the 2nd quarter. BBR Partners LLC now owns 25,000 shares of the company’s stock valued at $96,000 after buying an additional 10,000 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of 2seventy bio by 16.6% in the 2nd quarter. American Century Companies Inc. now owns 79,953 shares of the company’s stock valued at $308,000 after acquiring an additional 11,363 shares during the last quarter. Finally, Venator Management LLC grew its position in 2seventy bio by 49.2% in the second quarter. Venator Management LLC now owns 485,000 shares of the company’s stock worth $1,867,000 after acquiring an additional 160,000 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.

2seventy bio Price Performance

Shares of TSVT stock opened at $3.14 on Friday. The company has a market cap of $161.99 million, a PE ratio of -1.69 and a beta of 1.69. 2seventy bio, Inc. has a 1 year low of $2.78 and a 1 year high of $6.40. The stock’s 50 day simple moving average is $4.11 and its two-hundred day simple moving average is $4.31.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.